Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.500
-0.020 (-1.32%)
At close: Apr 1, 2025, 4:00 PM
1.517
+0.017 (1.15%)
After-hours: Apr 1, 2025, 5:59 PM EDT

Immuneering Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-61.04-53.47-50.51-33.54-17.04
Upgrade
Depreciation & Amortization
0.390.350.80.160.08
Upgrade
Loss (Gain) From Sale of Assets
0.0100.01--
Upgrade
Loss (Gain) From Sale of Investments
-0.26-1.02-0.170.13-
Upgrade
Stock-Based Compensation
6.55.734.061.81.09
Upgrade
Other Operating Activities
0.330.41--0.31-
Upgrade
Change in Accounts Receivable
-0.010.230.28-0.29
Upgrade
Change in Accounts Payable
-0.11-1.111.76-0.131.19
Upgrade
Change in Other Net Operating Assets
-0.810.12-0.280.750.36
Upgrade
Operating Cash Flow
-55-48.97-44.1-30.85-14.62
Upgrade
Capital Expenditures
-0.08-0.34-0.74-0.06-0.05
Upgrade
Cash Acquisitions
---0.07-
Upgrade
Investment in Securities
26.527.6442.57-75.63-
Upgrade
Investing Cash Flow
26.437.341.83-75.62-0.05
Upgrade
Issuance of Common Stock
5.4328.640.3121.6-
Upgrade
Other Financing Activities
-0.13-0.2-0.28-2.12-
Upgrade
Financing Cash Flow
5.328.440.02144.2637.98
Upgrade
Net Cash Flow
-23.26-13.23-2.2537.823.31
Upgrade
Free Cash Flow
-55.08-49.31-44.84-30.91-14.67
Upgrade
Free Cash Flow Margin
---14148.44%-1486.17%-634.83%
Upgrade
Free Cash Flow Per Share
-1.84-1.74-1.70-2.27-2.96
Upgrade
Levered Free Cash Flow
-33.65-31.1-25.99-18.59-8.25
Upgrade
Unlevered Free Cash Flow
-33.65-31.1-25.99-18.59-8.25
Upgrade
Change in Net Working Capital
0.40.33-2.23-0.69-1.31
Upgrade
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q